The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zavalishin I.A.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Peresedova A.V.

Research Center of Neurology, Moscow, Russia

Stoĭda N.I.

Gur'ianova O.E.

Arzumanian N.Sh.

Alekseeva N.S.

Eliseeva D.D.

Kafedra akusherstva i ginekologii im. S.S. Dobrotina Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Gulevskaia T.S.

Briukhov V.V.

Diagnosis and treatment of multiple sclerosis

Authors:

Zavalishin I.A., Peresedova A.V., Stoĭda N.I., Gur'ianova O.E., Arzumanian N.Sh., Alekseeva N.S., Eliseeva D.D., Gulevskaia T.S., Briukhov V.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(6): 89‑96

Views: 1215

Downloaded: 17

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Zavalishin IA, Peresedova AV, Stoĭda NI, et al. . Diagnosis and treatment of multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2011;111(6):89‑96. (In Russ.)

 
МСФ на ЯМ
Close metadata

Keywords:

treatment
multiple sclerosis

Authors:

Zavalishin I.A.

Nauchnyĭ tsentr nevrologii RAMN, Moskva

Peresedova A.V.

Research Center of Neurology, Moscow, Russia

Stoĭda N.I.

Gur'ianova O.E.

Arzumanian N.Sh.

Alekseeva N.S.

Eliseeva D.D.

Kafedra akusherstva i ginekologii im. S.S. Dobrotina Nizhegorodskoĭ gosudarstvennoĭ meditsinskoĭ akademii

Gulevskaia T.S.

Briukhov V.V.

List of references:

  1. Baidina E.V., Boiko A.N., Bryukhov V.V. i dr.Rezul'taty klinicheskogo issledovaniya rossiiskogo bioanaloga interferona-beta-1V. Nevrologicheskii vestnik 2010; T. XLII, vyp. 1: 41-48.
  2. Zavalishin I.A., Peresedova A.V., Stoida N.I. i dr.Sravnitel'nyi analiz effektivnosti immunomoduliruyushchei terapii rasseyannogo skleroza rebifom 22 mkg, betaferonom i kopaksonom (rezul'taty 3 let lecheniya). Zhurnal nevrologii i psikhiatrii im. S.S.Korsakova 2007, vypusk 4 "Rasseyannyi skleroz". S. 99-105.
  3. Shmidt T.E., Yakhno N.N.Rasseyannyi skleroz: rukovodstvo dlya vrachei. 2-e izd. M.: MEDpress-inform 2010; 272 s.
  4. Aharoni R., Kayhan B., Eilam R. et al.Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci USA 2003; 100: 14157-14162.
  5. Aharoni R., Arnon R., Eilam R.Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J Neurosci 2005; 25: 8217-8228.
  6. Barske C., Osinde M., Klein C. et al.FTY720 (fingolimod) and S1P-receptor 1 and 5 specific agonists increase the number of oligodendrocytes in vitro. Neurology 2008; 70: Suppl.1: A28 (abstract).
  7. Bartosik-Psujek H., Belniak E., Mitosek-Szewczyk K. et al.Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. Acta Neurol Scand 2004; 109: 390-392.
  8. Berger T.Current therapeutic recommendations in multiple sclerosis.
  9. Beutler E.Cladribine (2-chlorodeoxyadenosine). Lancet 1992; 340: 952-956.
  10. Biernacki K., Antel J.P., Blain M. et al.Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch Neurol 2005; 62, 4: 563-568.
  11. Boutros T., Croze E., Yong V.W.Interferon-β is a potent promoter of nerve growth factor production by astrocytes. J Neurochem 1997; 69: 939-946.
  12. Brenner T., Arnon R., Sela M. et al.Humoral and cellular immune responses to Copolymer 1 in multiple sclerosis patients treated with Copaxone. J Neuroimmunol 2001; 115: 152-160.
  13. Brinkmann V., Davis M.D., Heise C.E. et al.The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002; 277: 21453-21457.
  14. Clanet M., Montalban X.The future of multiple sclerosis therapies. - PAREXEL MMS Europe Ltd 2006; 51 p.
  15. Coelho R.P., Payne S.G., Bittman R. et al.The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther 2007; 323: 626-635.
  16. Cohen J.A. , Barkhof F., Comi G. et al.Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362, 5: 402-415.
  17. Comi G.Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol Sci 2008; 29 Suppl. 2: S253-255.
  18. Comi G., Martinelli V., Rodegher M. et al.Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomized, double-blind, placebo-controlled trial. Lancet 2009; 374 (9700): 1503-1511.
  19. Coyle P.K.Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 2008; 71, 24 Suppl: S3-7.
  20. De Stefano N., Curtin F., Stubinski B. et al.Rabid benefits of a new formulation of subcutaneous interferon beta-1 f in relapsing-remitting multiple sclerosis. Mult Scler 2010; 16, 7: 888-892.
  21. Dhib-Jalbut S.Glatiramer acetate (Copaxone®) therapy for multiple sclerosis. Pharmacol Ther 2003; 98: 245-255.
  22. European Study Group on Interferon beta-1b in Secondary Progressive MS. Placebo-controlled multicenter randomized trial of interferon β-1b in treatment of secondary progressive multiple sclerosis. Lancet. 1998; 352: 1491-1497.
  23. Foster C.A., Howard L.M., Schweitzer A. et al.Brain penetration ot the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther 2007; 323: 469-475.
  24. Freedman M.S.Induction vs. escalation of therapy for relapsing multiple sclerosis: the evidence. Neurol Sci 2008; 29, Suppl. 2: S250-252.
  25. Giovannoni G., Goodman A.Neutralizing anti-IFN-β antibodies, How much more evidence do we need to use them in practice? Neurology 2005; 65: 6-8.
  26. Giovannoni G., Barbarash O., Casset-Semanaz F. et al.Safety and immunogenicity of a new formulation of interferon β-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. Mult Scler 2009; 15: 219-228.
  27. Giovannoni G., Comi G., Cook S. et al.A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010; 362, 5: 416-426.
  28. Gneiss C., Tripp P., Reichartseder F. et al.Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler 2006; 12, 6: 731-737.
  29. Goodin D.S., Frohman E.M., Hurwitz B. et al.Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68, 13: 977-984.
  30. Guarnaccia J.B., Rinder H., Smith B.Preferential depletion of lymphocyte sub-populations by cladribine in a phase III clinical trial in multiple sclerosis. In: Program and abstracts of the World Congress on Treatment and Research in Multiple Sclerosis, Montreal, September 17-20, 2008 (poster).
  31. Jacobs L.D., Cookfair D.L., Rudick R.A. et al.Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann Neurol 1996; 39: 285-294.
  32. Jacobs L.D., Beck R.W., Simon J.H. et al.Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis.
  33. Janiec K., Wajgt A., Kondera-Anasz Z.Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. Med Sci Monit 2001; 7: 93-98.
  34. Johnson K.P., Brooks B.R., Cohen J.A. et al.Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.
  35. Johnson K.P., Calabresi P.A.Interferon-β-1b: prophylactic therapy in multiple sclerosis. Handbook of multiple sclerosis. Ed. S.D.Cook. 3nd ed. Marcel Dekker Inc 2001; 503-518.
  36. Kappos L., Polman C.H., Freedman M.S. et al.Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006; 67: 1242-1249.
  37. Kappos L., Radue E.W., O'Connor P. et al.A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362, 5: 387-401.
  38. Kopadze T., Dobert M., Leussink V.I. et al.Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis. Eur J Neurol 2009; 16: 409-412.
  39. Mandala S., Hajdu R., Bergstrom J. et al.Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 2002; 296: 346-349.
  40. Matloubian M., Lo C.G., Cinamon G. et al.Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1p receptor 1. Nature 2004; 427: 355-360.
  41. Mikol D.D., Barkhof F., Chang P. et al.Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008; 7: 10: 903-914.
  42. Miller D.H., Weinshenker B.G., Filippi M. et al.Diffential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008; 14: 1157-1174.
  43. Miron V.E., Jung C.G., Kim H.J. et al.FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008; 63: 61-71.
  44. Niezgoda A., Losy J., Mehta P.D.Effect of cladribine treatment on beta-2 micro-globulin and soluble intercellular adhesion molecule 1 (ICAM-1) in patients with multiple sclerosis. Folia Morphol. (Warsz) 2001; 60: 225-228.
  45. Panitch H.Prophylactic therapy - glatiramer acetate (Copaxone). Handbook of multiple sclerosis. Ed. S.D.Cook. 3nd ed. Marcel Dekker Inc 2001; 541-560.
  46. Pinschewer D.D., Ochsenbein A.F., Odermatt B. et al.FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol 2000; 164: 5761-5770.
  47. Polman C.H., O'Connor P.W., Havrdova E. et al.A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354, 22: 2387-2389.
  48. Polman C.H., Reingold S.C., Banwell B.et. al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald Criteria. Ann Neurol 2011; 69: 292-302.
  49. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing-remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
  50. Rice G.P., Filippi M., Comi G.Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Neurology 2000; 54: 1145-1155.
  51. Rudick R.A., Stuart W.H., Calabresi P.A. et al.Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006; 354: 9: 911-923.
  52. Schwab S.R., Cyster J.G.Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol 2007; 8: 1295-1301.
  53. Sorensen P.S., Deisenhammer F., Duda P. et al.Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis. Europ J Neurol 2005; 12: 817-827.
  54. SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Clinical results. Neurology 2001; 56: 1496-1504.
  55. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicentral, randomized double bind, placebo-controlled trial. Neurology 1993; 43: 655-661.
  56. Wiendl H., Toyka K.V., Rieckman P. et al.Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008; 255: 1449-1463.
  57. Yong V.W., Chabot S., Stuve O., Williams G.Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998; 51: 682-689.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.